Search

Displaying results 1901 - 1910 of 7540 in total
  1. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. … Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  2. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.

  3. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm. … of 776 nm.

  4. Drug

    Benzphetamine

    go.drugbank.com/drugs/DB00865
    ApprovedIllicit

    A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)

    Synonyms: (+)-N-benzyl-N,α-dimethylphenethylamine, (S)-(+)-N-benzyl-N,α-dimethylphenethylamineCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Bivalirudin

    go.drugbank.com/drugs/DB00006
    ApprovedInvestigational

    Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

  6. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

    Categories: Histamine H1 Antagonists, Non-Sedating
  7. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.

  8. Drug

    Interferon beta-1b

    go.drugbank.com/drugs/DB00068
    ApprovedInvestigational

    Produced in E. coli, no carbohydrates, MW=18.5kD

  9. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.

  10. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use.